300463 迈克生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入616,367-8.88%2,895,7703,608,4123,980,6473,703,877
减:营业总成本483,287-9.25%2,506,5782,763,4482,779,5242,719,945
    其中:营业成本262,495-13.13%1,295,3181,651,7711,673,9401,736,392
               财务费用3,828-38.48%23,31018,28957,86969,978
               资产减值损失(94)-98.15%(58,037)(23,973)(17,634)(17,732)
公允价值变动收益(1,583)-78.08%(7,077)(9,104)0--
投资收益1,850-51.15%8,59212,145395994
    其中:对联营企业和合营企业的投资收益0-100.00%42348395994
营业利润136,445-2.75%331,145817,3951,214,066989,690
利润总额135,9840.70%305,369789,0841,187,128969,766
减:所得税费用11,740-31.81%69087,378184,879148,411
净利润124,2445.45%304,679701,7051,002,248821,354
减:非控股权益3,802299.05%(7,939)(6,475)45,64427,436
股东净利润120,4423.05%312,619708,180956,604793,918

市场价值指针
每股收益 (元) *0.2005.26%0.5141.1731.7311.433
每股派息 (元) *----0.1550.3490.4710.431
每股净资产 (元) *10.5831.26%10.42510.2757.7256.815
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容